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Interpreting and comparing risks in the presence of
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Competing events are common in medical research. Ignoring them in the statistical analysis can
easily lead to flawed results and conclusions.This article uses a real dataset and a simple simulation
to show how standard analysis fails and how such data should be analysed
Martin Wolkewitz senior research fellow 1, Ben S Cooper senior research fellow 2 3, Marc J M Bonten
professor of molecular epidemiology of infectious diseases 4, Adrian G Barnett associate professor
of public health 5, Martin Schumacher professor of statistics in medicine 1
1Center for Medical Biometry and Medical Informatics, Institute for Medical Biometry and Statistics, Medical Center University of Freiburg, Germany;
2Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; 3Centre for Tropical Medicine,
Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK; 4Department of Medical Microbiology and Julius Center for Health
Sciences and Primary Care, Universitair Medical Center Utrecht, 3508 GA Utrecht, Netherlands; 5Institute of Health and Biomedical Innovation and
School of Public Health and Social Work, Queensland University of Technology, Brisbane, QLD 4059, Australia
Introduction
Survival or time-to-event analysis has become a widely used
statistical method in medical research.1 It provides valuable
insights into how the risk of the event of interest (such as death
or disease) depends on time.2However, the careless application
of survival models may easily lead to flawed results when basic
assumptions are not fulfilled. For instance, in a recent cluster
randomised trial3 not more than 4% of the study patients
acquired a primary bloodstream infection in hospital, but the
reported cumulative risk of such an infection was up to 25%.4
Results from a cohort study of hospitalised children in Kenya
reported no association between burns and nosocomial
bacteraemia5 even though the cumulative risk was three times
higher for children with burns.6 In a study of intensive care
patients7more than 95%were discharged alive, but their survival
plots predict a survival probability from the intensive care unit
of less than 20%.8 Such results are typical when so called
competing events prevent us from observing the event of interest
(such as primary bloodstream infection, nosocomial bacteraemia,
or death in intensive care unit).9
Checking model assumptions
In standard survival analysis we are concerned with the time to
some event of interest; a patient who has not experienced the
event at the end of follow-up is said to be censored. If we want
to determine the risk of the event having occurred by a certain
time, a fundamental assumption is that such censoring is not
associated with an altered chance of the event occurring at any
given moment.2
Often, one is interested in specific events such as death due to
cancer, but if a patient is censored due to death from another
cause the censoring assumption is violated (since the chance of
death is now zero). Any such event which causes censoring and
which is associated with an altered chance of the event of
interest occurring has to be treated as a competing event. Fatal
events are quite obvious competing events. For example, death
without prior relapse competes with relapse in oncology,9 10 and
death while waiting for a heart transplant is a competing event
for transplantation in cardiovascular research.11
Non-fatal competing events occur if these events change the
probability of experiencing the event of interest. If the event of
interest is mortality in hospitalised patients and patients are
followed up until discharge or death, discharge (alive) is a
competing event since discharged patients are usually in better
health (with an improved survival) than hospitalised patients.12
If nosocomial infection is the event of interest, discharge or
death without a nosocomial infection are competing events since
discharge usually precludes the observation of a nosocomial
infection.6 13
Real data example for cumulative risks
We use an example from hospital epidemiology; it is a random
sample from a full cohort study that is described in detail
elsewhere.14 In this example, of 1313 patients admitted to
hospital, 108 (8.2%) acquired a nosocomial pneumonia (termed
“infection” here) and 1189 (90.6%) were discharged (or died)
without a nosocomial infection. The remaining 16 (1.2%)
patients were administratively censored: they were still
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hospitalised at the end of study, and so it is not known which
type of event they would experience afterwards. In survival
analysis it is important to distinguish between risks (which
measure the chance of something happening per individual at
risk in a given time period) and hazard rates (which measures
risk per unit of time). The daily infection rate is defined as the
number of nosocomial infections in a sample divided by the
patient-days at risk:
Daily infection rate = (number of patients with a nosocomial
infections)/(number of patient-days at risk)
Patient-days at risk is the sum of each patient’s length of
infection-free hospital stay. In our example, the averaged time
at risk (time between admission and nosocomial infection,
discharge, or censoring, whichever comes first) was 12.9 days,
and there were 1313 patients and 16 953 patient-days at risk.
So the daily infection rate is 108/16 953 = 0.006 (0.6%).
During their hospital stay, patients may either acquire a
nosocomial infection or they are discharged without a
nosocomial infection. That means that discharge without a
nosocomial infection is a competing event for a nosocomial
infection. We therefore calculate the discharge rate without
infection as the number of discharges without infection divided
by the number of patient-days at risk:
Daily discharge rate without infection = (number of
discharges without infection)/(number of patient-days at
risk)
In our example, 1189 patients were discharged without an
infection, thus the daily discharge rate is 1189/16 953 = 0.07
(7%).
Relation between overall risks and daily
rates
The overall infection risk is related to the infection rate as
follows:
Overall infection risk = (daily infection rate)/{(daily infection
rate)+(daily discharge rate without infection)}
The number of patient-days at risk cancel out, in our example:
(108/16 953)/{(108/16 953)+(1189/16 953)} =
108/(108+1189) = 108/1297 = 0.082
Thus, the overall infection risk depends on the daily infection
but also (and this is crucial) on the competing event, the
discharge rate without infection.
Risk accumulates with time
Now, wewant to estimate how the risk of a nosocomial infection
and the risk to be discharged without a nosocomial infection
accumulate with the time from admission. If competing events
are accounted for, the cumulative risk (also known as the
cumulative incidence function) of nosocomial infection is a
product of two probabilities and, therefore, is itself a
probability.6 15 16 The first term is the probability that an event
happens up to time t (either acquiring an infection or to be
discharged without an infection), the second term is the
probability that this event is an infection. Thus, the cumulative
incidence function can be thought of as the probability of
observing a specific event up to time t. Separate cumulative risk
curves can be calculated for each event, in this case infection
and discharge without infection.
Figure 1⇓ shows the cumulative risk of nosocomial infection
and of hospital discharge. At every time point, the cumulative
probability of nosocomial infection, discharge, and remaining
infection-free in the hospital add up to 100%, the maximal value
for a probability (blue and red curves in fig 1⇓). For example,
at day 40 after admission, the cumulative risks are 8.2%
(nosocomial infection) and 86.1% (discharge), which add up to
94.3%, meaning that the probability to be in hospital without a
nosocomial infection is the remaining 5.7%. The other curves
in fig 1⇓ show results from a standard survival analysis (as, for
example, used in3), ignoring competing events. At day 40 after
admission, probabilities are 19.5% (nosocomial infection) and
94.4% (discharge), which add up to 114%, an impossible value
for a probability. The bias using the Kaplan-Meier approach is
exacerbated if the competing event is relatively common, as in
our data example where lots of admissions end in discharge. To
overcome this problemwe have to account for competing events.
What can happen when comparing risks
Now we consider how competing events affect our ability to
compare risks for an exposure of interest. For example, wemight
be interested to know whether age increases the risk of
nosocomial infection, or if a hospital-wide intervention reduced
the risk of nosocomial infection. If the exposure is associated
with the competing event then this can have surprising effects
on our risk estimates. We consider nine hypothetical scenarios
(table⇓ and fig 2⇓) and estimate the cumulative incidence
function according to a simple formula relating the interplay of
risks and rates.6 15 16
In scenarios 1-3, the exposure is not directly associated with
the competing event. Hence the daily infection rate ratios are
close to the overall infection risk ratios.
In scenario 4, the exposure has no effect on the daily infection
risk but decreases the discharge rate—for example, older and
younger patients have the same daily infection risk, but older
patients stay longer in hospital. This indirectly leads to a
increased risk of infection for exposed patients. On the other
hand, if exposed patients stay for less time in hospital (increased
discharge rate), the overall infection risk would be smaller
(scenario 5). Scenarios 4 and 5 show that the exposure can
indirectly increase or decrease the overall infection risk, even
though the exposure does not directly affect the daily infection
risk; it is just the indirect effect of prolonged (or shortened)
length of hospital stay that makes exposed patients more (or
less) likely to acquire an infection.
In scenario 6, the exposure directly increases the daily infection
risk, but exposed patients also have shorter hospital stays, which
eventually leads to an equal overall infection risk in both
exposure groups. However, the cumulative incidence function
differs, and exposed patients have a higher infection risk at
earlier times (fig 2⇓). An equal overall infection risk in both
exposure groups could also occur if exposed patients have a
much smaller daily infection risk but also stay longer in hospital
(scenario 7). Scenarios 6 and 7 show that an infection risk ratio
of 1 could occur with an infection rate ratio greater or lower
than 1 depending on how the exposure decreases or increases
the discharge rate.
Infection rate and risk ratios can even differ in sign (scenarios
8 and 9). In these scenarios, the time dependent infection risks
are crossing: soon after admission the infection risk for exposed
patients is lower than that for the unexposed group, and later it
is greater (scenario 8) or vice versa (scenario 9).
Ways of measuring effects
Methods are available to correctly analyse data in the presence
of competing risks.9 17 These include estimating the risks of
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events over time and determining how exposures of interest
affect risk.
As a starting point, one should calculate hazard ratios for each
event: one daily rate ratio for infection (the event of interest)
and one daily rate ratio for discharge without infection (the
competing event). These can be obtained from separate Cox
proportional hazards regression models or one Coxmodel using
duplicated records.17 This approach provides an aetiological
exploration of risk factors and shows how risk factors are
associated with each event; direct and indirect effects can be
distinguished.
An additional analysis is necessary to make conclusions on
cumulative risks. This is possible with subdistribution hazard
ratios, which are interpreted as a comparison of the cumulative
incidence functions. As a time-averaged risk comparison,
subdistribution hazard ratios extend overall risk ratios. This
type of analysis makes use of what is known as a Fine and Gray
model.18
Both approaches are necessary to understand how risk factors
are directly and indirectly associated with events of interest
when there are competing events.19 The methods can also
account for some important issues which we have neglected in
this article, such as time dependent hazard rates, multiple
competing events, readmissions and potential confounders.
Time dependent hazards and cumulative incidence functions
should be estimated using the Nelson-Aalen andAalen-Johansen
estimator17 to relax our assumption of time constant hazard rate.
There are also alternative methods to analyse competing event
data.20
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Summary box
In the presence of competing events, classic survival curves (Kaplan-Meier) overestimate cumulative risks and are therefore inadequate
Risk accumulates differently when there are competing events and should be displayed as cumulative incidence functions for each
event. Subdistribution hazard ratios measure the effect of exposures in terms of cumulative incidence functions
Reporting one hazard ratio for the event of interest is incomplete, and it does not compare cumulative risks. For an aetiological exploration
it is necessary to report hazard ratios also for the competing events
Table
Table 1| Details of nine possible scenarios for rates of nosocomial pneumonia and of discharge from hospital without infection in a cohort
of patients admitted to hospital. Infection and discharge rates are set for an exposed and an unexposed patient group. Then, rate, overall
risk ratios and cumulative incidence functions (cumulative infection risks) are calculated based on these values (see fig 2). Note that the
overall infection risk ratio compares only the plateau of the curves in the figure. The simulation code is available in the technical appendix
of this paper
Overall infection risk
ratio
({i1/(i1+d1)}/{i0/(i0+d0)})Discharge rate ratio (d1/d0)
Daily discharge rates
Infection rate ratio (i1/i0)
Daily infection rates
Scenario Unexposed (d0)Exposed (d1)Unexposed (i0)Exposed (i1)
110.150.1510.020.021
0.37510.150.150.330.030.012
2.6710.150.1530.010.033
1.830.50.20.110.020.024
0.5520.10.210.020.025
130.10.330.010.036
10.330.30.10.330.030.017
1.450.330.30.10.50.020.018
0.6930.10.320.010.029
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Figures
Fig 1Cumulative incidence functions of nosocomial pneumonia and discharge from hospital without nosocomial pneumonia
in a cohort of 1313 patients admitted to hospital. We use publicly available data from a German cohort study.14 Data and
statistical code are available in the technical appendix of this paper
Fig 2 Cumulative incidence functions of nosocomial pneumonia under nine hypothetical scenarios (see table⇓ and text for
details of the scenarios)
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